Research
Hormonal
Liraglutide and semaglutide may provide benefits for weight loss and glycaemic control in people living with HIV.
Practitioners may consider liraglutide and semaglutide for weight management in HIV patients, particularly those with diabetes.
StrongSupportsmedium confidence
Clinical experience is limited to two clinical cases of diabetic people with HIV using liraglutide after which a successful weight loss and glycaemic control were observed.
Why this rating
Based on clinical observations mentioned in the abstract.
Source
<scp>GLP</scp>‐1 agonists for people living with <scp>HIV</scp> and obesity, is there a potential?
Leena Zino et al. · HIV Medicine · 2023
DOI 10.1111/hiv.13521
case_studyCited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →